Moxalactam therapy for a wide spectrum of bacterial infections in adults.
We evaluated the efficacy and toxicity of moxalactam during treatment of 45 documented infections in 36 patients. A majority of patients received 4.5 g of moxalactam per day. There was a good clinical response in 42 of the 45 (94%) infections, including 3 bacteremias, 20 skin and soft tissue infecti...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1981
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181515/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6457555/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.19.5.740 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|